Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

Leukemia Research

Volumn 48, Issue , 2016, Pages 84-91

  Dorer, David J ^a   Knickerbocker, Ronald K ^a   Baccarani, Michele ^b   Cortes, Jorge E ^c   Hochhaus, Andreas ^d   Talpaz, Moshe ^e   Haluska, Frank G ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

BCR ABL1; Chronic myeloid leukemia; Dose intensity; Philadelphia chromosome; Ponatinib; Tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PONATINIB; TRIACYLGLYCEROL LIPASE; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTERY OCCLUSION; ARTHRALGIA; ARTICLE; BCR ABL1 GENE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DOSE; DRUG DOSE INTENSITY; DRUG DOSE REDUCTION; DRUG SAFETY; GENE; GENE MUTATION; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PANCREATITIS; PERIPHERAL VASCULAR DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; THROMBOCYTOPENIA; TIME; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPLICATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; TIME FACTOR;

CLINICAL TRIALS AS TOPIC; EXANTHEMA; HEART FAILURE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATITIS; PYRIDAZINES; TIME FACTORS;

EID: 84982836632     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2016.07.007     Document Type: Article

References (33)

1. [1] Soverini, S., De Benedittis, C., Machova Polakova, K., Brouckova, A., Horner, D., Iacono, M., et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 122 (2013), 1634–1648.
2. [2] Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001), 876–880.
3. [3] Nicolini, F.E., Corm, S., Lê, Q.H., Sorel, N., Hayette, S., Bories, D., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20 (2006), 1061–1066.
4. [4] Müller, M.C., Cortes, J.E., Kim, D.W., Druker, B.J., Erben, P., Pasquini, R., et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114 (2009), 4944–4953.
5. [5] Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.W., Müller, M.C., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 27 (2009), 4204–4210.
6. [6] Khoury, H.J., Cortes, J.E., Kantarjian, H.M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.W., et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119 (2012), 3403–3412.
7. [7] O'Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A., Rivera, V.M., Wang, F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16 (2009), 401–412.
8. [8] Deininger, M.W., Hodgson, J.G., Shah, N.P., Cortes, J.E., Kim, D.W., Nicolini, F.E., et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 127 (2016), 703–712.
9. [9] Parker, W.T., Yeung, D.T., Yeoman, A.L., Altamura, H.K., Jamison, B.A., Field, C.R., et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood 127 (2016), 1870–1880.
10. [10] Cortes, J.E., Kim, D.W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 369 (2013), 1783–1796.
11. [11] J. Pinilla-Ibarz, J.E. Cortes, D.W. Kim, P.D. le Coutre, R. Paquette, C. Chuah, et al. Clinical impact of ponatinib dose modification in patients with Philadelphia chromosome-positive leukemias [poster 4007] Presented at: Annual Meeting of the American Society of Hematology December 7–10, New Orleans, LA 2013.
12. [12] Cortes, J.E., Kantarjian, H., Shah, N.P., Bixby, D., Mauro, M.J., Flinn, I., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367 (2012), 2075–2088.
13. [13] Lipton, J.H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 17 (2016), 612–621.
14. [14] Cortes, J., Kim, D.W., Pinilla-Ibarz, J., le Coutre, P.D., Paquette, R., Chuah, C., et al. Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial [abstract P234]. Haematologica, 100(suppl. (1)), 2015, 64.
15. [15] Jabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 16 (2015), 1547–1555.
16. [16] Douxfils, J., Haguet, H., Mullier, F., Chatelain, C., Graux, C., Dogné, J.M., Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol.(February), 2016, 10.1001/jamaoncol.2015.5932 Epub ahead of print.
17. [17] Moslehi, J.J., Deininger, M., Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol. 33 (2015), 4210–4218.
18. [18] Li, W., Croce, K., Steensma, D.P., McDermott, D.F., Ben-Yehuda, O., Moslehi, J., Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J. Am. Coll. Cardiol. 66 (2015), 1160–1178.
19. [19] Valent, P., Hadzijusufovic, E., Schernthaner, G.H., Wolf, D., Rea, D., le Coutre, P., Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125 (2015), 901–906.
20. [20] Mayer, K., Gielen, G.H., Willinek, W., Müller, M.C., Wolf, D., Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib. Leukemia 28 (2014), 976–977.
21. [21] Le Coutre, P., Rea, D., Abruzzese, E., Dombret, H., Trawinska, M.M., Herndlhofer, S., et al. Severe peripheral arterial disease during nilotinib therapy. J. Natl. Cancer Inst. 103 (2011), 1347–1348.
22. [22] Aichberger, K.J., Herndlhofer, S., Schernthaner, G.H., Schillinger, M., Mitterbauer-Hohendanner, G., Sillaber, C., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am. J. Hematol. 86 (2011), 533–539.
23. [23] Tasigna [Package Insert]. 2015, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
24. [24] Sprycel [Package Insert]. 2015, Bristol-Myers Squibb Company, Princeton, NJ.
25. [25] Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boque, C., et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123 (2014), 494–500.
26. [26] Iclusig [Package Insert]. 2015, ARIAD Pharmaceuticals, Inc, Cambridge, MA.
27. [27] Iclusig [Summary of Product Characteristics]. 2016, ARIAD Pharma Ltd, Leatherhead, United Kingdom.
28. [28] Gleevec [Package Insert]. 2015, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
29. [29] Bosulif [Package Insert]. 2016, Pfizer, Inc, New York, NY.
30. [30] Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12 (2006), 7374–7379.
31. [31] Nicolini, F.E., Hayette, S., Corm, S., Bachy, E., Bories, D., Tulliez, M., et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 92 (2007), 1238–1241.
32. [32] Nicolini, F.E., Mauro, M.J., Martinelli, G., Kim, D.W., Soverini, S., Müller, M.C., et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 114 (2009), 5271–5278.
33. [33] Nicolini, F.E., Ibrahim, A.R., Soverini, S., Martinelli, G., Müller, M.C., Hochhaus, A., et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 98 (2013), 1510–1516.